Physician profile
Amber Fleming
NPI 1538846746
$3,387.77
in general payments reported to CMS, 2019-2025
20 companies · $943 in 2025
The $943 reported for 2025 was more than what 84% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $702 · 2024: $1,743 · 2025: $943.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,370 · Education: $18.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,369.77 |
| Education | $18.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $481.29 | 2023-2025 | Verquvo, Capvaxive |
| Astrazeneca Pharmaceuticals LP | $458.30 | 2023-2025 | Farxiga, Airsupra, Wainua |
| E.R. Squibb & Sons, L.L.C. | $347.09 | 2023-2025 | Camzyos, Eliquis |
| Janssen Pharmaceuticals, INC | $264.30 | 2023-2024 | Xarelto |
| Philips North America LLC | $236.23 | 2023-2024 | (5091) Amb Mon & Diag Und, (Cm9) Amb Mon & Diag Und |
| Scpharmaceuticals INC. | $233.99 | 2023-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $213.82 | 2023-2025 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $213.75 | 2024-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $197.02 | 2024-2025 | |
| Cvrx, INC. | $165.77 | 2025 | Barostim Neo System |
| Medtronic, INC. | $158.39 | 2023-2024 | Micra, Onyx Frontier |
| Lilly USA, LLC | $114.87 | 2025 | |
| Inspire Medical Systems, INC. | $91.99 | 2023-2025 | Inspire |
| Lexicon Pharmaceuticals, INC. | $63.23 | 2024 | Inpefa |
| Pfizer INC. | $37.28 | 2025 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, Plc | $36.78 | 2024 | Arcalyst |
| Esperion Therapeutics, INC. | $20.52 | 2024 | Nexletol |
| Bridgebio Pharma, INC. | $19.36 | 2025 | Attruby |
| Novo Nordisk INC | $17.38 | 2025 | Ozempic, Rybelsus |
| Boston Scientific Corporation | $16.41 | 2024 | Watchman Access System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber Fleming listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.